The Effects of IGF-1 on TNF-α-Treated DRG Neurons by Modulating ATF3 and GAP-43 Expression via PI3K/Akt/S6K Signaling Pathway

Upregulation of the pro-inflammatory cytokine tumor necrosis factor α (TNF-α) is involved in the development and progression of numerous neurological disorders. Recent reports have challenged the concept that TNF-α exhibits only deleterious effects of pro-inflammatory destruction, and have raised the awareness that it may play a beneficial role in neuronal growth and function in particular conditions, which prompts us to further investigate the role of this cytokine. Insulin-like growth factor-1 (IGF-1) is a cytokine possessing powerful neuroprotective effects in promoting neuronal survival, neuronal differentiation, neurite elongation, and neurite regeneration. The association of IGF-1 with TNF-α and the biological effects, produced by interaction of IGF-1 and TNF-α, on neuronal outgrowth status of primary sensory neurons are still to be clarified. In the present study, using an in vitro model of primary cultured rat dorsal root ganglion (DRG) neurons, we demonstrated that TNF-α challenge at different concentrations elicited diverse biological effects. Higher concentration of TNF-α (10 ng/mL) dampened neurite outgrowth, induced activating transcription factor 3 (ATF3) expression, reduced growth-associated protein 43 (GAP-43) expression, and promoted GAP-43 and ATF3 coexpression, which could be reversed by IGF-1 treatment; while lower concentration of TNF-α (1 ng/mL) promoted neurite sprouting, decreased ATF3 expression, increased GAP-43 expression, and inhibited GAP-43 and ATF3 coexpression, which could be potentiated by IGF-1 supplement. Moreover, IGF-1 administration restored the activation of Akt and p70 S6 kinase (S6K) suppressed by higher concentration of TNF-α (10 ng/mL) challenge. In contrast, lower concentration of TNF-α (1 ng/mL) had no significant effect on Akt or S6K activation, and IGF-1 administration activated these two kinases. The effects of IGF-1 were abrogated by phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. These data imply that IGF-1 counteracts the toxic effect of higher concentration of TNF-α, while potentiates the growth-promoting effect of lower concentration of TNF-α, with the node for TNF-α and IGF-1 interaction being the PI3K/Akt/S6K signaling pathway. This study is helpful for interpretation of the association of IGF-1 with TNF-α and the neurobiological effects elicited by interaction of IGF-1 and TNF-α in neurological disorders.

[1]  Tsonwin Hai,et al.  ATF3 and stress responses. , 1999, Gene expression.

[2]  R. Dantzer,et al.  Tumor necrosis factor-alpha induces neuronal death by silencing survival signals generated by the type I insulin-like growth factor receptor. , 2000, Annals of the New York Academy of Sciences.

[3]  R. Dantzer,et al.  Tumor Necrosis Factor‐α Induces Neuronal Death by Silencing Survival Signals Generated by the Type I Insulin‐Like Growth Factor Receptor , 2000 .

[4]  Atsushi Tokunaga,et al.  Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury , 2000, Molecular and Cellular Neuroscience.

[5]  J. Richert,et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.

[6]  S. Mohand-Said,et al.  Neurodegenerative and Neuroprotective Effects of Tumor Necrosis Factor (TNF) in Retinal Ischemia: Opposite Roles of TNF Receptor 1 and TNF Receptor 2 , 2002, The Journal of Neuroscience.

[7]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[8]  Prashanth Kenchappa,et al.  Rescue of TNFalpha-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. , 2004, Journal of neuroscience research.

[9]  S. Ohtori,et al.  Extracorporeal shockwaves induce the expression of ATF3 and GAP-43 in rat dorsal root ganglion neurons , 2006, Autonomic Neuroscience.

[10]  E. Papadopoulos,et al.  Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. , 2006, Arthritis and rheumatism.

[11]  C. Woolf,et al.  The transcription factor ATF-3 promotes neurite outgrowth , 2006, Molecular and Cellular Neuroscience.

[12]  S. Dudek,et al.  TNF-α Preconditioning Protects Neurons via Neuron-Specific Up-Regulation of CREB-Binding Protein1 , 2009, The Journal of Immunology.

[13]  A. Fromont,et al.  Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. , 2009, Cytokine.

[14]  A. Basbaum,et al.  Differential ATF3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuli , 2010, PAIN.

[15]  John T. Schmidt,et al.  GAP43 phosphorylation is critical for growth and branching of retinotectal arbors in zebrafish , 2010, Developmental neurobiology.

[16]  J. Gómez-Reino,et al.  Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. , 2011, Seminars in arthritis and rheumatism.

[17]  A. Saleh,et al.  Tumor necrosis factor-α elevates neurite outgrowth through an NF-κB-dependent pathway in cultured adult sensory neurons: Diminished expression in diabetes may contribute to sensory neuropathy , 2011, Brain Research.

[18]  J. Gómez-Reino,et al.  Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. , 2011, Seminars in arthritis and rheumatism.

[19]  R. V. Vugt,et al.  Local insulin-like growth factor I expression is essential for Purkinje neuron survival at birth , 2010, Cell Death and Differentiation.

[20]  P. Scheurich,et al.  A TNF Receptor 2 Selective Agonist Rescues Human Neurons from Oxidative Stress-Induced Cell Death , 2011, PloS one.

[21]  BDNF-, IGF-1- and GDNF-Secreting Human Neural Progenitor Cells Rescue Amyloid β-Induced Toxicity in Cultured Rat Septal Neurons , 2011, Neurochemical Research.

[22]  L. Wang,et al.  Increased inflammation and brain injury after transient focal cerebral ischemia in activating transcription factor 3 knockout mice , 2012, Neuroscience.

[23]  G. Raivich,et al.  Activating Transcription Factor 3 and the Nervous System , 2012, Front. Mol. Neurosci..

[24]  X. Mariette,et al.  Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. , 2013, Rheumatology.

[25]  Masayuki Kobayashi,et al.  Changes in expression of growth-associated protein-43 in trigeminal ganglion neurons and of the jaw opening reflex following inferior alveolar nerve transection in rats. , 2013, European journal of oral sciences.

[26]  D. Dexter,et al.  Parkinson disease: from pathology to molecular disease mechanisms. , 2013, Free radical biology & medicine.

[27]  B. Baune,et al.  TNF-α and its receptors modulate complex behaviours and neurotrophins in transgenic mice , 2013, Psychoneuroendocrinology.

[28]  R. Dolmetsch,et al.  SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients , 2013, Nature.

[29]  C. Frank,et al.  Directed Axonal Outgrowth Using a Propagating Gradient of IGF‐1 , 2014, Advanced materials.

[30]  Y. Zang,et al.  The role of TNF-alpha/NF-kappa B pathway on the up-regulation of voltage-gated sodium channel Nav1.7 in DRG neurons of rats with diabetic neuropathy , 2014, Neurochemistry International.

[31]  R. Pang,et al.  TNF-α-mediated JNK activation in the dorsal root ganglion neurons contributes to Bortezomib-induced peripheral neuropathy , 2014, Brain, Behavior, and Immunity.

[32]  P. Voulgari,et al.  Demyelination and other neurological adverse events after anti-TNF therapy. , 2014, Autoimmunity reviews.

[33]  H. Maegawa,et al.  Gene Therapy for Neuropathic Pain by Silencing of TNF-α Expression with Lentiviral Vectors Targeting the Dorsal Root Ganglion in Mice , 2014, PloS one.

[34]  Jiangwen Zhang,et al.  ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and retaining muscle innervation , 2014, Proceedings of the National Academy of Sciences.

[35]  B. Topçu,et al.  The relationship between changes in the expression of growth associated protein-43 and functional recovery of the injured inferior alveolar nerve following transection without repair in adult rats. , 2015, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[36]  J. Ito,et al.  Insulin-like growth factor 1: A novel treatment for the protection or regeneration of cochlear hair cells , 2015, Hearing Research.

[37]  D. Pearse,et al.  MASH1/Ascl1a Leads to GAP43 Expression and Axon Regeneration in the Adult CNS , 2015, PloS one.

[38]  Giorgia Quadrato,et al.  The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury. , 2015, Brain : a journal of neurology.

[39]  Qian Zhang,et al.  The Red Nucleus TNF-α Participates in the Initiation and Maintenance of Neuropathic Pain Through Different Signaling Pathways , 2015, Neurochemical Research.

[40]  A. Herrmann,et al.  Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration , 2016, Proceedings of the National Academy of Sciences.

[41]  A. Kolevzon,et al.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders , 2016, Neuroscience & Biobehavioral Reviews.

[42]  Alan R. Mardinly,et al.  Sensory experience regulates cortical inhibition by inducing IGF-1 in VIP neurons , 2016, Nature.

[43]  B. Knöll,et al.  Atf3 mutant mice show reduced axon regeneration and impaired regeneration-associated gene induction after peripheral nerve injury , 2016, Open Biology.

[44]  Zhijun Zhang,et al.  Inflammatory Cytokines and Alzheimer’s Disease: A Review from the Perspective of Genetic Polymorphisms , 2016, Neuroscience Bulletin.

[45]  Heh-In Im,et al.  Pathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders , 2016, International neurourology journal.

[46]  Targeting inflammation as a treatment modality for neuropathic pain in spinal cord injury: a randomized clinical trial , 2016, Journal of Neuroinflammation.